A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
December 16, 2014DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
December 01, 2014DURECT to Present at the Oppenheimer Healthcare Conference
November 11, 2014DURECT Provides Update on POSIDUR™ Program
November 03, 2014DURECT Corporation Announces Third Quarter 2014 Financial Results and Update of Programs